BiondVax rises on positive data on COVID drug preclinical study
06/01/2023 14:34
** U.S.-listed shares of Israel-based drug developer
BiondVax Pharmaceuticals Ltd BVXV.O up 11.9% at $3.54
** Co says its experimental nasal drug, NanoAb, for
potential treatment and prevention of COVID-19 "virtually
eliminated" the presence of coronavirus in the lungs of hamsters
** BVXV says hamsters infected with SARS-COV-2 virus and
then treated with NanoAb had over 30-times lower viral presence
in the lungs on average compared to placebo
** Co plans first early-stage human trial this year
** BVXV shares fell 84.4% in the past 12 months
(Reporting by Mariam E Sunny)
((Mariam.ESunny@thomsonreuters.com;))